Press Releases 

Helomics Launches GeneFx Colon to Identify Patients with High Risk Stage II Colon Cancer

PITTSBURGH – LONDON March 15, 2016 - Helomics® Corporation, a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services, announced today the launch of GeneFx® Colon, a prognostic multi-gene expression assay designed to identify colon cancer patients who are likely to experience recurrence within five years following initial surgery. GeneFx Colon is designed to enable physicians to make informed personalized treatment decisions about potentially adding adjuvant chemotherapy. GeneFx Colon is a proprietary gene signature test utilizing an individual patient’s RNA expression and

 Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • Twitter Basic Square

© 2020 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon